Bookmark! (press Ctrl+D)

Richard Becker, MD, director of the University of Cincinnati Heart, Lung and Vascular Institute discusses the phase 2 clinical trial for razuprotafib, an investigational drug that activates a key pathway for stabilizing blood vessels in the lung and other organs in patients with moderate to severe cases of the respiratory illness caused by COVID-19.

source

LEAVE A REPLY

Please enter your comment!
Please enter your name here